开放标签、多中心、随机、II期研究:EpSSG与ITCC评估在儿童及青少年转移性软组织肉瘤化疗中加入贝伐珠单抗(BERNIE研究)
BERNIE研究随机分配154例转移性横纹肌肉瘤(RMS)或非横纹肌肉瘤软组织肉瘤(NRSTS)儿童及青少年,比较化疗联合或不联合贝伐珠单抗的疗效。主要终点无事件生存(EFS)在两组间无统计学显著改善(分层HR=0.93,95%CI 0.61-1.41,P=0.72)。联合贝伐珠单抗耐受性可,但未显著改善EFS。
要点
- 转移性RMS/NRSTS患儿化疗联合贝伐珠单抗未显著改善EFS(分层HR=0.93,P=0.72)。
- RMS亚组EFS的HR=1.24(95%CI 0.73-2.09),NRSTS亚组HR=0.64(95%CI 0.32-1.26)。
- 客观缓解率化疗组36.0% vs 联合组54.0%,差值18.0%(95%CI 0.6-35.3)。
核心结论
- 在转移性RMS/NRSTS儿童及青少年中,化疗联合贝伐珠单抗耐受性可,但主要终点EFS未显示统计学显著改善。
研究设计与样本
- 开放标签、多中心、随机、II期研究,纳入年龄≥6个月至<18岁的转移性RMS或NRSTS患者。
- 154例患者随机分配至单纯化疗组(n=80)或化疗联合贝伐珠单抗组(n=74)。
- 治疗方案包括诱导化疗(4周期IVADo+5周期IVA,±贝伐珠单抗)、手术和/或放疗,后续维持化疗(12周期低剂量环磷酰胺+长春瑞滨,±贝伐珠单抗)。
- 主要终点为经独立影像学审查委员会评估的EFS。
主要发现
- 中位EFS:单纯化疗组14.9个月(95%CI 10.8-35.9),联合贝伐珠单抗组20.6个月(95%CI 15.2-24.9),分层HR=0.93(95%CI 0.61-1.41,P=0.72)。
- RMS患者(n=103)EFS的HR=1.24(95%CI 0.73-2.09),NRSTS患者(n=49)HR=0.64(95%CI 0.32-1.26)。
- 客观缓解率:单纯化疗组36.0%(95%CI 25.2-47.9),联合贝伐珠单抗组54.0%(95%CI 40.9-66.6),差值18.0%(95%CI 0.6-35.3)。
- 无治疗相关死亡,联合贝伐珠单抗未增加3/4级毒性发生率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the role of bevacizumab as part of the multi-modality treatment of children and adolescents with metastatic rhabdomyosarcoma (RMS) or non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). PATIENTS AND METHODS: Eligible patients aged ≥6 months to <18 years were randomised to receive induction chemotherapy (four cycles of IVADo + five cycles of IVA, ±bevacizumab), surgery and/or radiotherapy, followed by maintenance chemotherapy (12 cycles of low-dose cyclophosphamide + vinorelbine, ±bevacizumab). The primary objective was event-free survival (EFS) evaluated by an independent radiological review committee. RESULTS: One hundred and fifty-four patients were randomised to receive chemotherapy alone (n = 80) or with bevacizumab (n = 74). At the data cut-off for the primary efficacy analysis, median EFS was 14.9 months (95% confidence interval [CI]: 10.8-35.9) with chemotherapy and 20.6 months (95% CI: 15.2-24.9) with bevacizumab plus chemotherapy (stratified hazard ratio [HR] = 0.93; 95% CI: 0.61-1.41; P = 0.72). The HR for EFS in patients with RMS (n = 103) was 1.24 (95% CI: 0.73-2.09) versus 0.64 (95% CI: 0.32-1.26) for those with NRSTS (n = 49). Objective response rate was 36.0% (95% CI: 25.2-47.9) with chemotherapy and 54.0% (95% CI: 40.9-66.6) with bevacizumab plus chemotherapy (difference of 18.0%; 95% CI: 0.6-35.3). There were no treatment-related deaths and no increased incidence of grade 3/4 toxicities with bevacizumab. CONCLUSION: The addition of bevacizumab to chemotherapy appeared tolerable in children and adolescents with metastatic RMS/NRSTS, but the primary end-point of EFS did not show statistically significant improvement. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00643565.
引用
- Chisholm JC, Merks JHM, Casanova M, et al. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Eur J Cancer. 2017. PMID: 28738258. doi:10.1016/j.ejca.2017.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。